Browse Lung cancer, Non-small cell topic

Subtopics (19)

Articles

1-100 out of 100 article(s)

Title	Author	Type	Date	Words
Curis Publishes Preclinical Data for Heat Shock Protein 90 Molecule in Erlotinib-Resistant Non-Small Cell Lung Cancer.			Dec 4, 2009	1338
ENDOCYTE PATENT ON VITAMIN RECEPTOR BINDING ANTI-CANCER AGENTS.			Dec 1, 2009	618
Nereus Pharmaceuticals Presents Positive Interim Data from the ADVANCE Study, a Randomized Phase 2 Clinical Trial of Plinabulin (NPI-2358) in Non-Small Cell Lung Cancer at the 2009 EORTC-NCI-AACR Conference.		Conference news	Nov 23, 2009	833
Canada : Canada s Med BioGene to File for US IPO.			Nov 19, 2009	361
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer.		Report	Nov 17, 2009	1517
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer.			Nov 16, 2009	758
Bend Memorial Clinic Pursues Recruitment in Lung Cancer Trial.			Nov 11, 2009	734
Japan : Japan Approves Avastin For Non-Small Cell Lung Cancer (Roche AG).			Nov 9, 2009	74
Endocyte Awarded Patent for Vitamin Receptor Binding Drug Delivery Conjugates.			Oct 27, 2009	608
United States : Peregrine Pharma lung cancer trial shows promise.			Oct 12, 2009	189
Asuragen Awarded More Than $3.8 Million in New NIH Small Business Grants.			Oct 7, 2009	472
ArQule Provides Clinical Update on ARQ 197.			Oct 5, 2009	1047
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation.			Sep 24, 2009	1150
Biotech drops drug application in Europe.			Sep 23, 2009	205
Cetuximab drug with chemo may cut death risk in lung cancer patients.			Sep 22, 2009	310
Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents.			Sep 18, 2009	1449
IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option - More Often than They Realize.		Clinical report	Sep 15, 2009	521
Lung cancer patients' pre-treatment life quality can predict odds of survival.			Sep 3, 2009	224
BI lung cancer trials.			Sep 1, 2009	269
Research and Markets: Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning.			Aug 27, 2009	393
Endocyte Announces Positive Results from a Phase II Clinical Study of EC145 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).		Clinical report	Aug 11, 2009	563
Adventrx lays out strategy for chemotherapy drug.	Chambers, Heather	Brief article	Aug 10, 2009	176
Two significant advances in treating lung cancer announced.			Aug 9, 2009	396
Celera Presents Data Replicating Its Immunodiagnostic Assay to Detect Lung Cancer from Blood Serum.			Aug 4, 2009	1528
Results from a Phase 2 Study of ABRAXANE[R] In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer.		Conference news	Aug 3, 2009	1700
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy.		Clinical report	Aug 1, 2009	1436
Response Genetics to Present New Data at the 13th World Conference on Lung Cancer Supporting the Use of Gene Expression to Help Personalize Cancer Therapy Selection.		Conference news	Jul 31, 2009	1095
DxS Collaborates with AstraZeneca to Provide a Companion Diagnostic for IRESSA[TM].			Jul 31, 2009	424
New targeted therapy delivers chemo directly to ovarian cancer cells.			Jul 30, 2009	429
Reportlinker Adds Lung Cancer Therapeutics.			Jul 16, 2009	2001
Abraxis BioScience Completes Enrollment of Pivotal Phase III Advanced Lung Cancer Study Evaluating ABRAXANE[R] Vs. Taxol[R].		Clinical report	Jul 14, 2009	1711
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.			Jul 13, 2009	1202
CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer.			Jul 7, 2009	528
Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer.			Jul 7, 2009	1250
Hormone therapy raises lung ca death risk.	Dales, Mary Jo M.		Jul 1, 2009	552
Antigenics' QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline's Malaria Vaccine.			Jun 17, 2009	633
OSI Pharmaceuticals Announces Acceptance of Tarceva Supplemental New Drug Application for Review by the U.S. Food and Drug Administration.			Jun 15, 2009	1350
ASCO Presentations Highlight Findings from Clinical Trials with ArQule's c-MET Inhibitor, ARQ 197.			Jun 1, 2009	2442
Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Anti-PD-1 Antibody at American Society of Clinical Oncology Annual Meeting.			Jun 1, 2009	1309
Characteristics of lung adenocarcinoma cases according to smoking history/Akciger adenokarsinomlu olgularin sigara oykusune gore ozellikleri.	Ak, Guntulu; Metintas, Muzaffer; Yildirim, Huseyin; Metintas, Selma; Erginel, Sinan; Alatas, Fusun	Report	Jun 1, 2009	3212
ZIOPHARM Presents Positive Data from Phase I Study of Palifosfamide in Combination with Doxorubicin at ASCO.			May 31, 2009	978
Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer.		Clinical report	May 30, 2009	1726
Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer.		Clinical report	May 30, 2009	1208
Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy.			May 30, 2009	1744
Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab.			May 30, 2009	1659
Research and Markets: Cancer Drug Discoveries: What the Future Holds for the Non-Small Cell Lung Cancer Market and Therapeutic Approaches.			May 26, 2009	774
Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Pfizer Inc, Eli Lilly, Amgen and Biogen.			May 18, 2009	594
Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer.			May 15, 2009	2115
Concordia Pharmaceuticals Reports Encouraging Clinical Data in Patients with K-Ras Mutations Treated with First-in-Class Ras Antagonist, Salirasib.			May 14, 2009	1087
SuperGen's MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients.			May 4, 2009	526
mTOR as a validated cancer target.		Brief article	May 1, 2009	191
Atlas strengthens NSCLC treatments.		Brief article	May 1, 2009	240
Response Genetics Expands Proprietary ResponseDX: Lung[TM] and ResponseDX: Colon[TM] Genetic Tests to Include Additional Patented Biomarkers Associated With Chemotherapy Response.			Apr 30, 2009	986
Celera Presents Data Describing an Immunodiagnostic Assay to Detect Lung Cancer from Blood Serum.			Apr 21, 2009	1411
Preclinical Data Presented on ARIAD's Investigational mTOR Inhibitor, Deforolimus, in Lung Cancer and Other Solid Tumor Models.		Clinical report	Apr 20, 2009	984
Encouraging Results Published on Use of TomoTherapySM in Lung Cancer Treatment.			Apr 9, 2009	1115
Endocyte Announces Positive Interim Results from Phase II Clinical Trial of EC145 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).		Clinical report	Mar 25, 2009	681
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer.			Mar 19, 2009	1210
Biothera Receives Approval to Launch Two Phase II Lung Cancer Trials.			Mar 12, 2009	445
Research and Markets: Lung Cancer Drug Pipeline Update 2009.			Mar 4, 2009	368
ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Advanced Non-Small Cell Lung Cancer.		Clinical report	Mar 2, 2009	1002
Novel platinum-based anti-tumour compound developed.			Feb 12, 2009	287
Novelos Therapeutics and Mundipharma Sign Exclusive Collaboration Agreement in Europe and Japan.			Feb 11, 2009	869
Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer.			Feb 2, 2009	1211
Popular cancer drug 'increases blood clot risk'.			Dec 3, 2008	458
Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN.			Dec 2, 2008	824
Radiofrequency ablation treats malignant lung nodules.	McBride, Deborah	Brief article	Dec 1, 2008	229
Efficacy of cisplatin and vinorelbine in patients with metastatic non-small cell lung carcinoma/ Metastatik kucuk hucreli disi akciger karsinomlu hastalarda sisplatin ve vinorelbinin etkinligi.	Yilmaz, Ufuk; Halilcolar, Huseyin; Yildirim, Yasemin; Yapicioglu, Sena; Unsal, Ipek; Mahlec, Ceyda	Clinical report	Dec 1, 2008	2750
Tarceva[R] (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer.			Nov 26, 2008	739
Popular cancer drug 'increases blood clot risk'.			Nov 25, 2008	458
Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Commences Patient Enrollment.		Report	Nov 11, 2008	662
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer.			Nov 7, 2008	1267
United States: Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination.		Drug overview	Nov 1, 2008	454
New technique monitors patients With NSCLC.	McBride, Deborah		Nov 1, 2008	625
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer.		Clinical report	Oct 6, 2008	1604
Two drugs don't boost lung cancer survival: Roche.			Oct 6, 2008	468
United States: Response Genetics partners with NeoGenomics to offer cancer tests.			Oct 3, 2008	165
Manage patients with non-small cell lung cancer: as seen in the Clinical Journal of Oncology Nursing.	Becze, Elisa		Oct 1, 2008	947
Response Genetics Launches National Sales Strategy for Its ResponseDX(TM) Tests Through Exclusive Agreement With NeoGenomics Laboratories and Formation of Sales Team.			Sep 29, 2008	939
Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008.		Clinical report	Sep 15, 2008	1013
Important Updates to the NCCN Drugs & Biologics Compendium(TM) Non-Small Cell Lung Cancer.			Sep 10, 2008	679
Genes may predict lung cancer aggressiveness.	McBride, Deborah	Brief article	Sep 1, 2008	307
Biomarkers allow doctors to match therapy to patient.		Conference news	Sep 1, 2008	216
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced.			Aug 29, 2008	2114
Cyclacel Announces Recommendations of Data Review Committee for Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial.		Clinical report	Aug 28, 2008	1112
Bio-Reference Laboratories, Inc. Announces K-ras Testing Availability Through GenPath.			Aug 6, 2008	451
China: China Medical Systems gets SFDA approval for Phase II trial for cancer treatment.			Aug 1, 2008	91
Maintenance therapy may delay lung cancer growth.	McBride, Deborah		Aug 1, 2008	339
Radiofrequency Ablation Yields High Proportions of Sustained Complete Responses in Patients with Lung Cancer.			Jul 14, 2008	909
Cyclacel Publishes Study of Seliciclib Synergy with Tarceva and Herceptin in Journal Clinical Cancer Research.			Jul 14, 2008	1284
Novelos Therapeutics Receives 6th U.S. Patent.			Jun 30, 2008	483
New Report 'Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements' Has Identified 104 Drugs in the NSCLC Pipeline, 15% of Which Are in Late-Phase Development.			Jun 18, 2008	401
M. D. Anderson and Aureon Laboratories to Evaluate Biomarkers Associated with Non-Small Cell Lung Cancer.			Jun 10, 2008	555
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development New Development Programs to Include Response Prediction to Ovarian Cancer Treatment, Predicting Risk of Gastric Cancer Recurrence, and Differentiation of Small Cell From Non-Small Cell Lung Cancer.			Jun 1, 2008	661
India: Intas Biopharma to Market Lung Cancer Drug Gefitinib in India.			May 30, 2008	509
Congress speakers to address non-small cell lung cancer, translational research, and cancer journey directives.			Mar 1, 2007	453
Talactoferrin Alpha receives fast-track designation for the treatment of non-small cell lung cancer.	McBride, Deborah		Jan 1, 2007	603
Peroxisome Proliferator-Activated Receptor g and Induction of Differentiation in Non-small Cell Lung Cancer.			Aug 1, 2000	2462
Cancer patients find relief in new drugs.		Clinical report	Aug 1, 1997	615
Breast cancer drug shows promise for other cancers.			Jan 1, 1997	431